Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, strengthening its executive leadership as the company prepares for a planned U.S. securities exchange listing and advances its lead candidate L-DOS47 into the next stage of clinical development.
Middleton brings more than 30 years of experience in pharmacy, law, and the global life sciences industry. A qualified life sciences lawyer and registered clinical pharmacist, she has advised pharmaceutical and biotechnology companies across the product life cycle, including research and development, clinical programs, regulatory strategy, and corporate transactions. Her career includes senior legal roles at Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. As General Counsel, she will oversee Helix's legal affairs, governance, compliance, and strategic transactions.
Browning has over 30 years of experience leading global clinical development programs across biotechnology, pharmaceutical, and academic sectors. He has overseen more than 30 Phase I-III clinical studies, from first-in-human through regulatory approval, and has built global oncology clinical operations teams. His expertise spans immunotherapies, targeted therapies, antibody-drug conjugates, and cell therapies. As Vice President of Clinical Operations, he will lead operational planning and execution of Helix's clinical programs, including the LDOS007 study.
Thomas Mehrling, MD, PhD, Chief Executive Officer, stated: "The next stage of Helix's evolution demands a different kind of company than the one we were building two years ago. As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization." He added that the preparation of a base shelf prospectus and the completion of the auditor review of second-quarter financials are part of a clear capital markets roadmap.
The appointments come as Helix advances L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company plans to initiate LDOS007, a Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC). Additionally, Helix is building the legal, governance, and operational infrastructure required for its next growth phase.
For more information, visit Helix BioPharma's website.
